Drug Profile
CVN 424
Alternative Names: CVN-424Latest Information Update: 31 Oct 2023
Price :
$50
*
At a glance
- Originator Cerevance
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Dopamine D2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease